The Lancet Oncology· Dan Liu, Zikun Peng, Wei Zhang, Cui Feng, Ping Wang, Jundong Li, Yuanjia Wen, Wanying Shan, Yu Xia, Huayi Li, Bingquan Li, Ronghua Liu, Mingfu Wu, Zhen Li, Rong Liu, Gang Chen, Ya Wang, Xiaofei Jiao, Xiao Li, Cheng Liu, Rutie Yin, Shengtao Zhou, Maomao Li, Zhifeng Xia, Yu Dong, Shanyang He, Yi Huang, COCPO Consortium, Kun Song, Li Hong, Ding Ma, Yong Fang, Qinglei Gao·· 9 天前AI 评分37
新辅助尼拉帕利（niraparib）单药治疗不可切除、同源重组缺陷阳性高级别浆液性卵巢癌（NANT）：一项多中心、单臂、II期临床试验
[Articles] Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial
AI 导读
NANT试验显示，新辅助尼拉帕利（niraparib）在部分最初不适合初次肿瘤细胞减灭术的HRD阳性晚期卵巢癌患者中显示抗肿瘤活性，并使R0切除成为可能。该策略仍属研究性治疗，需通过随机试验与标准铂类联合紫杉烷类新辅助化疗进行比较验证。
来源：The Lancet Oncology · thelancet.com